US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:CANF

1 2 3 4 5 6 7 8 9 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
25/04/2024	06:00	Business Wire	Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	AMEX:CANF	Can Fite BioPharma Ltd
15/04/2024	06:00	Business Wire	Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	AMEX:CANF	Can Fite BioPharma Ltd
03/04/2024	06:00	Business Wire	Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	AMEX:CANF	Can Fite BioPharma Ltd
28/03/2024	06:00	Business Wire	Can-Fite Reports 2023 Financial Results and Clinical Update	AMEX:CANF	Can Fite BioPharma Ltd
11/03/2024	06:27	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	AMEX:CANF	Can Fite BioPharma Ltd
11/03/2024	06:00	Business Wire	Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference	AMEX:CANF	Can Fite BioPharma Ltd
28/02/2024	06:00	Business Wire	Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada	AMEX:CANF	Can Fite BioPharma Ltd
14/02/2024	14:32	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	AMEX:CANF	Can Fite BioPharma Ltd
30/01/2024	06:00	Business Wire	Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	AMEX:CANF	Can Fite BioPharma Ltd
29/01/2024	06:00	Business Wire	Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study	AMEX:CANF	Can Fite BioPharma Ltd
07/01/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	AMEX:CANF	Can Fite BioPharma Ltd
28/12/2023	15:16	Edgar (US Regulatory)	Form F-3/A - Registration statement by foreign private issuers: [Amend]	AMEX:CANF	Can Fite BioPharma Ltd
20/12/2023	06:00	Business Wire	The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies	AMEX:CANF	Can Fite BioPharma Ltd
18/12/2023	06:00	Business Wire	Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	AMEX:CANF	Can Fite BioPharma Ltd
12/12/2023	15:15	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	AMEX:CANF	Can Fite BioPharma Ltd
04/12/2023	06:00	Business Wire	Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development	AMEX:CANF	Can Fite BioPharma Ltd
30/11/2023	06:00	Business Wire	Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update	AMEX:CANF	Can Fite BioPharma Ltd
22/11/2023	15:20	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	AMEX:CANF	Can Fite BioPharma Ltd
21/11/2023	12:53	GlobeNewswire Inc.	Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds	AMEX:CANF	Can Fite BioPharma Ltd
21/11/2023	06:00	Business Wire	Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson	AMEX:CANF	Can Fite BioPharma Ltd
01/11/2023	06:00	Business Wire	Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track	AMEX:CANF	Can Fite BioPharma Ltd
30/10/2023	06:00	Business Wire	Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action	AMEX:CANF	Can Fite BioPharma Ltd
26/10/2023	06:00	Business Wire	Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs	AMEX:CANF	Can Fite BioPharma Ltd
09/10/2023	06:00	Business Wire	Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies	AMEX:CANF	Can Fite BioPharma Ltd
27/09/2023	06:00	Business Wire	Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)	AMEX:CANF	Can Fite BioPharma Ltd
07/09/2023	06:00	Business Wire	Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference	AMEX:CANF	Can Fite BioPharma Ltd
01/09/2023	15:16	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	AMEX:CANF	Can Fite BioPharma Ltd
31/08/2023	06:00	Business Wire	Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies	AMEX:CANF	Can Fite BioPharma Ltd
24/08/2023	06:10	Business Wire	Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome	AMEX:CANF	Can Fite BioPharma Ltd
18/08/2023	06:00	Business Wire	Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis	AMEX:CANF	Can Fite BioPharma Ltd

Showing the most relevant articles for your search:AMEX:CANF

1 2 3 4 5 6 7 8 9 Próxima >

US Dollar vs MXN

Verizon Communications

Gold vs US Dollar

Bank of America

Energy Select Sector SPDR

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones